Company intelligence / Profile preview

Nanjing Tianqing Technology Fund

Ownership: Private
Development stage: Phase 3

Overview

NJCTTQ has multiple approved drugs in China and globally for oncology and other indications; active clinical pipeline includes small molecules and biologics up to Phase 3 trials.

Therapeutic areas: OncologyHematologyWomen's HealthMen's Health
Modalities: Small moleculesbiosimilarsherbal medicinesbiological products (including bispecific antibodies)
Industry: Pharma

Drug pipeline

3 assets

LM-302

Phase 3

Indications: Gastric cancer, Gastroesophageal junction cancer, Pancreatic cancer, Biliary tract cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Abpro ($4B immuno-oncology deal)Evive Biotech licensing/commercialization partnership for Ryzneuta™

Beyond the preview

Go deeper on Nanjing Tianqing Technology Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Tianqing Technology Fund.

Explore the full profile